PIB TrackerRevised MRPs of 1,364 anti-cancer formulations take effect
From 9 November 2026, 85 companies have reported cuts for 1,364 anti-cancer formulations covering 121 drugs, with 679 brands down by over 50 per cent and savings estimated at Rs 3,540.38 crore a year.
What happened
- The NPPA, under the Department of Pharmaceuticals, capped trade margins on the MRP of 137 anti-cancer drugs on the advice of a DGHS Expert Committee; revised MRPs apply from 9 November 2026.
- By 8 November, 85 companies had reported new MRPs for 1,364 formulations covering 121 drugs.
- 679 brands report cuts above 50 per cent, and the highest reported cut is 96.45 per cent.
- Annual consumer savings are estimated at Rs 3,540.38 crore.
- Prices can be verified on the pack, the Pharma Sahi Daam app or nppa.gov.in; complaints go to Pharma Jan Samadhan or helpline 1800-111-255.
For Prelims
- NPPA: the National Pharmaceutical Pricing Authority, under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers; it fixes and revises drug prices and enforces the pricing order.
- Trade margin cap: on 17 October 2026 NPPA capped trade margins on 137 non-scheduled anti-cancer drugs at 30 per cent of MRP, under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
- Paragraph 19: allows the Government, in extraordinary circumstances and in the public interest, to fix or cap the price of any drug beyond the standard rules.
- Scheduled vs non-scheduled: scheduled medicines are those in the First Schedule to the DPCO, 2013 (the National List of Essential Medicines) and carry a ceiling price; for non-scheduled ones an annual MRP rise is limited to 10 per cent.
- NLEM 2022: the National List of Essential Medicines, published by the Ministry of Health and Family Welfare, lists 388 medicines and is the base of the First Schedule to the DPCO, 2013.
- Trade Margin Rationalisation: the 2019 pilot capped the margin on 42 non-scheduled anti-cancer drugs and cut the prices of 526 brands.
- Pharma Sahi Daam: NPPA's mobile app for checking medicine prices; complaints go to the Pharma Jan Samadhan portal.
- Out-of-pocket spending: its share of total health expenditure fell from about 62 per cent in 2014-15 to about 43 per cent in 2021-22, according to PIB releases.
For UPSC: NPPA trade-margin cap on 137 anti-cancer drugs, effective 9 November 2026: 85 companies, 1,364 formulations, 121 drugs; 679 brands cut over 50 per cent; Rs 3,540.38 crore savings.
What it is NOT: The release does not say how many of the 137 drugs have not yet reported new prices, how the Rs 3,540.38 crore estimate was computed, or what share of cancer patients buy through hospital pharmacies and tenders. It gives no penalties for non-compliance and says nothing on how State Drug Controllers will check retail stock. It does not name the drugs with the largest cuts or say whether any manufacturer has withdrawn a product.
For Mains
Syllabus: GS2.13 · GS2.10 · Linkage L1
Anchor
Cancer treatment can bankrupt a family because the retail price of a drug often bears little relation to what the hospital pays. A cap on the trade margin targets that gap directly.
Substantiation (data)
NPPA capped margins on 137 drugs at 30 per cent of MRP. By 8 November, 85 companies had revised 1,364 formulations; 679 brands fell by over 50 per cent, and savings are put at Rs 3,540.38 crore.
Position
Margin capping works on the distribution chain without fixing the manufacturer's price. It extends a 2019 pilot of 42 drugs that cut 526 brands, and gives patients a pack price, an app and a complaint portal.
Counterpoint
The savings figure is an estimate built on company-reported prices, and a cap on retail margin does not reach hospital procurement or diagnostics. Supply availability of the cheaper brands is an open question.
Way forward
Publish drug-wise before-and-after prices, audit compliance in hospital pharmacies, update the list of 137 on a fixed cycle, monitor stock-outs, and link the cap to bulk procurement and insurance package rates.
Conclusion
The reported cuts are large. The test is whether the lower prices reach the patient's bill and whether supply holds.
Deploys into: Drug price regulation and affordability of health care · Out-of-pocket health expenditure · Regulators and consumer grievance tools · Public-interest powers under the pricing order
Ministry of Chemicals and Fertilizers · 2026-11-09 · PRID 2334268 · PIB source ↗